This cross-sectional study examined responses of the isolated cystic a
rtery to 3 alpha-adrenoceptor agonists and the effects of 2 antagonist
s in relation to subjects' blood pressures. Potency of the 3 amines st
udied was: alpha-methylnorepinephrine > norepinephrine > phenylephrine
. Responses to clonidine were trivial (< 5% of maximum) and remained <
25% of maximum in the presence of subthreshold concentrations of angi
otensin II. A weak trend for increased potency of alpha-methylnorepine
phrine was noted in arteries of subjects with higher blood pressures (
r = 0.268, p = 0.027). There was no relationship between blood pressur
e and pA(2) for yohimbine. The pA(2) for prazosin could not be calcula
ted because of a decline in maximal responses but prazosin was clearly
more potent than yohimbine, The decline in maximal responses to norep
inephrine and phenylephrine after prazosin treatment was related to su
bjects' diastolic blood pressures (r = -0.400, p = 0.003), There were
no significant relationships between these measurements of vascular re
sponsiveness and a family history of hypertension, There were also no
significant relationships betwen these measurements of vascular respon
siveness and plasma norepinephrine levels, alpha(2)-adrenoceptor bindi
ng or platelets of beta(2)-adrenoceptor binding of lymphocytes, The ma
jor postjunctional a-adrenoceptors in this artery are of the alpha(1)
type. The data suggest that differences in potency of alpha(2)-adrenoc
eptor agonists in relation to blood pressure may be due to differences
in the alpha(2)-adrenoceptor but are not likely due to a difference i
n binding to the receptor itself. The explanation for the effect of pr
azosin on maximal responses to alpha-adrenoceptor agonists in relation
ship to blood pressure in the present study requires further study, If
the results in blood cell adrenoceptors are parallel to those in cyst
ic artery, increased potency of alpha(2)-adrenoceptor agonists in the
artery in subjects with higher blood pressure is not due to an increas
ed number of adrenoceptors and therefore is most likely due to differe
nces in postreceptor excitation-contraction coupling. Future experimen
ts should utilize preparations such as subcutaneous resistance vessels
where alpha(2)-adrenoceptors are more predominant.